Concepedia

Publication | Open Access

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study

DOIFull Paper Access

159

Citations

28

References

2016

Year

Andreas Stallmach, C. Langbein, Raja Atreya, Tony Bruns, K Ende, Jochen Hampe, Franz Hartmann, Markus F. Neurath, Jochen Maul, Renate Schmelz,
Alimentary Pharmacology & Therapeutics

Abstract

Among patients who started vedolizumab for active inflammatory bowel disease, clinical remission rates are 21-25% after 54 weeks.

References

YearCitations

Page 1